文献速递膀胱癌与上尿路尿路上皮癌

肌层浸润性膀胱癌新辅助化疗降期后隐匿性淋巴结转移风险

Occult Nodal Metastases in Patients Down-Staged to Nonmuscle Invasive Disease Following Neoadjuvant Chemotherapy.
PubMed 文献 · Urology · 2020-04-05

本研究基于美国国家癌症数据库2004–2013年数据,纳入接受多药新辅助化疗后行根治性膀胱切除加盆腔淋巴结清扫的cT2-4aN0M0膀胱癌患者,评估临床完全或部分缓解者中隐匿性淋巴结转移的风险。结果显示完全缓解和部分缓解者的隐匿性淋巴结转移率分别为4.9%和5.4%,年龄、性别、种族、合并症、淋巴血管侵犯及变异组织学与隐匿性淋巴结转移无显著关联。结论提示即使临床完全缓解,仍存在膀胱外隐匿病变风险。

要点

  • 新辅助化疗后病理完全缓解者中4.9%存在隐匿性淋巴结转移。
  • 病理部分缓解者中5.4%存在隐匿性淋巴结转移。
  • 年龄、性别、合并症及变异组织学与隐匿性淋巴结转移无显著关联。

核心结论

  • 新辅助化疗后临床完全或部分缓解的患者仍存在隐匿性淋巴结转移风险,完全缓解者为4.9%,部分缓解者为5.4%。
  • 膀胱保留策略可能适用于经过严格筛选并密切随访的患者,但需警惕膀胱外隐匿病变。

研究设计与样本

  • 回顾性队列研究,查询美国国家癌症数据库2004–2013年数据。
  • 纳入cT2-4aN0M0膀胱癌接受多药新辅助化疗后根治性膀胱切除加盆腔淋巴结清扫的患者,排除非尿路上皮为主组织学及部分膀胱切除者。

主要发现

  • 共17917例患者接受根治性膀胱切除,其中14.9%(n=2673)接受新辅助化疗。
  • 完全病理缓解(ypT0)和部分病理缓解(ypTa、Tis、T1)分别占13.1%和14.5%。
  • cT2、cT3、cT4患者分别有14.7%、9.0%、6.9%达到pT0。
  • 完全缓解和部分缓解者中隐匿性淋巴结转移率分别为4.9%和5.4%。
  • 年龄、性别、种族、合并症、淋巴血管侵犯及变异组织学与隐匿性淋巴结转移无显著关联。

临床怎么用

  • 对新辅助化疗后临床完全缓解的患者,应告知其仍存在隐匿性淋巴结转移风险,膀胱保留决策需谨慎。
  • 膀胱保留策略应仅限于严格筛选并密切随访的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the risk of occult nodal metastasis in patients with muscle invasive bladder cancer who exhibit a complete or partial clinical response to neoadjuvant chemotherapy (NAC) and assess a potential role for "bladder sparing" management given that the gold standard treatment, radical cystectomy (RC), is associated with high morbidity. METHODS: We queried the National Cancer Database for bladder cancer from 2004 to 2013 including patients with cT2-4aN0M0 bladder cancer who underwent multiagent NAC followed by RC and pelvic lymphadenectomy and excluding patients with nonurothelial predominant histology and those undergoing partial cystectomy. Student's t test was used to evaluate patients' demographics, presence of co-morbid conditions, and pathologic findings, notably the presence of lymphovascular invasion and variant histology. RESULTS: We identified 17,917 patients who underwent RC. Of these, 14.9% (n = 2673) received NAC before RC. About 13.1% and 14.5% of patients had complete (ypT0) and partial (ypTa, Tis, and T1) pathologic response, respectively. These 14.7% of cT2, 9.0% of cT3, and 6.9% of cT4 patients exhibited pT0 status on final pathology. And 4.9% of complete and 5.4% of partial responders demonstrated occult nodal metastases. Age, sex, ethnicity, the presence of co-morbidities, LVI, and variant histology were not significantly associated with occult nodal metastasis. CONCLUSION: While bladder preservation may be a viable option in patients who are carefully selected and closely followed after NAC, patients undergoing NAC may be at risk of occult disease outside of the bladder despite an otherwise clinical complete response diagnosed with cross-sectional imaging, cystoscopy, TURBT, and cytology.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Nassiri N, Ghodoussipour S, Maas M, et al. Occult Nodal Metastases in Patients Down-Staged to Nonmuscle Invasive Disease Following Neoadjuvant Chemotherapy. Urology. 2020. PMID: 32268173. doi:10.1016/j.urology.2020.03.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。